Literature DB >> 12115836

Solution equilibria of deferoxamine amides.

Peter M Ihnat1, Jonathan L Vennerstrom, Dennis H Robinson.   

Abstract

The physico-chemical solution properties of deferoxamine were modified by acylating the terminal amino group with short-chain aliphatic, succinic, and methylsulphonic moieties. The analog iron(III)-binding constants and stabilities under physiological conditions were determined to confirm that the iron binding ability of the parent molecule was retained following modification. The proton dissociation constants of the lipophilic deferoxamine analogs were determined by potentiometric titration and nonlinear least-squares analysis. However, because the iron(III) binding complex is fully formed below pH 2, the metal-ligand equilibria could not be studied using potentiometric methods. The iron binding constants of the deferoxamine analogs were determined by spectrophotometrically following the proton-dependent exchange of iron with EDTA in the pH range of 4.0 to 6.5 and solving mass balance equations. The proton-dissociation constants and the iron binding constants of the lipophilic deferoxamine analogs were comparable to those of deferoxamine. However, at physiological conditions, the iron-binding complex of the most lipophilic butylamide derivative was slightly less stable and the succinamide derivative complex was slightly more stable. Like deferoxamine, the hydroxamate groups of the analogs were unhindered and free to form a 1:1 coordination complex with iron(III). Consequently, changes in aqueous solvation, conformation, and steric interference, imparted by the modifications at the terminal amino group of deferoxamine, may have affected the stabilities of the iron(III) complex and the efficiency of iron binding. Copyright 2002 Wiley-Liss Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115836     DOI: 10.1002/jps.10168

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors:  Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal:  Transl Res       Date:  2010-05-27       Impact factor: 7.012

2.  Desferrioxamine inhibits protein tyrosine nitration: mechanisms and implications.

Authors:  Margaret A Adgent; Giuseppe L Squadrito; Carol A Ballinger; David M Krzywanski; Jack R Lancaster; Edward M Postlethwait
Journal:  Free Radic Biol Med       Date:  2012-06-15       Impact factor: 7.376

3.  A manganese photosensitive tricarbonyl molecule [Mn(CO)3(tpa-κ3N)]Br enhances antibiotic efficacy in a multi-drug-resistant Escherichia coli.

Authors:  Namrata Rana; Helen E Jesse; Mariana Tinajero-Trejo; Jonathan A Butler; John D Tarlit; Milena L von Und Zur Muhlen; Christoph Nagel; Ulrich Schatzschneider; Robert K Poole
Journal:  Microbiology (Reading)       Date:  2017-09-28       Impact factor: 2.777

4.  π-Plasmon absorption of carbon nanotubes for the selective and sensitive detection of Fe3+ ions.

Authors:  William Cheung; Mehulkumar Patel; Yufeng Ma; Yuan Chen; Qiaoqiao Xie; Jenny V Lockard; Yuan Gao; Huixin He
Journal:  Chem Sci       Date:  2016-04-18       Impact factor: 9.825

5.  Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

Authors:  Evangelia Vlachodimitropoulou; Yu-Lin Chen; Maciej Garbowski; Pimpisid Koonyosying; Bethan Psaila; Martha Sola-Visner; Nichola Cooper; Robert Hider; John Porter
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

6.  Conjugates of desferrioxamine and aromatic amines improve markers of iron-dependent neurotoxicity.

Authors:  Rodrigo R V Carvalho; Tanara V Peres; Cleber W Liria; M Teresa Machini; Michael Aschner; Breno P Espósito
Journal:  Biometals       Date:  2021-01-03       Impact factor: 2.949

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.